Brought to you by 
J&J agrees to acquire Alza for stock
30 Apr 2001
Executive Summary
Johnson & Johnson has agreed to acquire drug delivery company Alza in a tax-free pooling of interests. Based on J&J's pre-announcement trading average of $90.41 per share, the transaction would be worth a total of $13.1bn.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
J&J agrees to acquire Alza for stock
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice